Mabwell (Shanghai) Bioscience Subidiary Grants License for Anti-Cancer Injection

Mabwell (Shanghai) Bioscience subsidiary Jiangsu Taikang Biopharmaceutical granted Qilu Pharmaceutical a new drug project license for its 8MW0511 injection, according to a Friday filing with the Shanghai bourse.

The drug is suitable for adult patients with non-myeloid malignant neoplasms or cancerous tumors who are taking myelosuppressive anticancer drugs that could cause febrile neutropenia or fever with low neutrophils, the filing said.

Under the agreement, Taikang will receive a one-time non-refundaable down payment of 380 million yuan and sales milestone payments of up to 500 million yuan as well as up to a double-digit percentage of the net sales of licensed products, the filing said.

Mabwell (Shanghai) Bioscience granted an exclusive license to Calico Life Sciences for its IL-11 targeted therapeutics, including the 9MW3811 monoclonal antibody against tumors and fibrosis, according to a Friday filing with the Shanghai bourse.

Under the agreement, Mabwell will receive a $25 million down payment for the agreement.

Mabwell will also be eligible for up to $571 million in proximal, development, registration and commercialization milestone payments, as well as tiered royalties based on net sales, the filing said.

Shares surged 20% at the close of trading Friday.

Mabwell (Shanghai) Bioscience granted an exclusive license to Calico Life Sciences for its IL-11 targeted therapeutics, including the 9MW3811 monoclonal antibody against tumors and fibrosis, according to a Friday filing with the Shanghai bourse.

Under the agreement, Mabwell will receive a $25 million down payment for the agreement.

Mabwell will also be eligible for up to $571 million in proximal, development, registration and commercialization milestone payments, as well as tiered royalties based on net sales, the filing said.

Shares surged 20% at the close of trading Friday.

Chinese stocks closed mixed on Friday amid a decline in industrial profits in May and a possible easing of trade tensions with the US.

The Shanghai Composite Index, the main gauge of Chinese stocks, slid 0.7% or by 24.23 points to 3,424.23. The Shenzhen Component Index gained 0.3% or by 35.07 points to 10,378.55.

Industrial profits fell 9.1% year over year in May, and slipped 1.1% in the first five months of 2025 to 2.720 trillion yuan, the country's statistics bureau said Friday.

The US and China have reached a trade understanding, which both initially agreed upon in Geneva in May. Under the terms, China will have to scrap its rare earth export curbs while the US should remove its countermeasures, Bloomberg News reported Friday, US Commerce Secretary Howard Lutnick.

Meanwhile, factory activity in the country may have contracted for a third consecutive month in June to 49.7, albeit still higher than the 49.5 figure in the previous month. Manufacturing PMI data is due for release Monday.

In corporate news, Mabwell Bioscience surged 20% at the close of trading Friday after granting Calico Life Sciences an exclusive license for the 9MW3811 monoclonal antibody.

Chinese stocks closed mixed on Friday amid a decline in industrial profits in May and a possible easing of trade tensions with the US.

The Shanghai Composite Index, the main gauge of Chinese stocks, slid 0.7% or by 24.23 points to 3,424.23. The Shenzhen Component Index gained 0.3% or by 35.07 points to 10,378.55.

Industrial profits fell 9.1% year over year in May, and slipped 1.1% in the first five months of 2025 to 2.720 trillion yuan, the country's statistics bureau said Friday.

The US and China have reached a trade understanding, which both initially agreed upon in Geneva in May. Under the terms, China will have to scrap its rare earth export curbs while the US should remove its countermeasures, Bloomberg News reported Friday, US Commerce Secretary Howard Lutnick.

Meanwhile, factory activity in the country may have contracted for a third consecutive month in June to 49.7, albeit still higher than the 49.5 figure in the previous month. Manufacturing PMI data is due for release Monday.

In corporate news, Mabwell Bioscience surged 20% at the close of trading Friday after granting Calico Life Sciences an exclusive license for the 9MW3811 monoclonal antibody.

Mabwell (Shanghai) Bioscience is planning to buy back between 25 million yuan and 50 million yuan of its shares.

The shares will be repurchased for up to 35.00 yuan apiece within 12 months from board approval, according to a Thursday filing with the Shanghai bourse.

Shares of the biopharmaceutical company closed 2% lower Thursday.